Pathstone Family Office’s Myriad Genetics MYGN Stock Holding History

Pathstone Family Office’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-15	Closed	–	–	1096
2020 Q4	$0	Hold	15	–	–	﹤0.01%	1270
2020 Q3	$0	Hold	15	–	–	﹤0.01%	926
2020 Q2	$0	Sell	15 -72	-83%	-$1.02K	﹤0.01%	887
2020 Q1	$1K	Buy	+87	New	+$1.84K	﹤0.01%	723
2019 Q2	–	Sell	-89	Closed	-$3K	–	809
2019 Q1	$3K	Hold	89	–	–	﹤0.01%	699
2018 Q4	$3K	Buy	+89	New	+$3.2K	﹤0.01%	424

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Pathstone Family Office's MYGN Position: Q1 2021 in Review

Pathstone Family Office sold out of Myriad Genetics (MYGN) in Q1 2021, closing a stake of 15 shares.

Pathstone Family Office first reported a position in MYGN in Q4 2018 and held it in 6 quarters. The position peaked at $3K in Q1 2019. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Pathstone Family Office reported no remaining Myriad Genetics position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 15 Myriad Genetics shares in Q1 2021.
Pathstone Family Office first reported a position in Myriad Genetics in Q4 2018 and held it in 6 quarters.
Pathstone Family Office's Myriad Genetics position peaked at $3K in Q1 2019.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.